<p>Humacyte, Inc.（纳斯达克股票代码：HUMA - 获取免费报告）的股价在周二交易中下跌了 8.9%。股价最低达到 5.48 美元，最后交易价为 5.51 美元。在交易过程中，共有 1,366,508 股股票交易，较平均交易量 2,181,580 股下降了 37%。该股票此前收盘价为 6.05 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>近期有几位研究分析师发布了关于该公司的报告。BTIG 研究将 Humacyte 的目标股价从 8.00 美元上调至 11.00 美元，并在 7 月 15 日星期一的一份研究报告中给予该股票 “买入” 评级。康泰菲兹杰拉德重申了对 Humacyte 的 “超重” 评级，并在 7 月 2 日星期二的一份报告中设定了 7.00 美元的价格目标。最后，Benchmark 重申了对 Humacyte 的 “买入” 评级，并在 8 月 12 日星期一的一份研究报告中设定了 15.00 美元的价格目标。一位研究分析师对该股票进行了持有评级，而另外四位则给予了该股票买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “中等买入”，目标股价为 8.60 美元。</p>
<p><strong>查看我们关于 HUMA 的最新报告</strong></p>
<h2>Humacyte 股价下跌 8.8%</h2>
<p>该公司的市值为 6.5734 亿美元，市盈率为-5.57，β系数为 1.52。该股票的 50 天移动平均价格为 6.86 美元，200 天移动平均价格为 5.47 美元。该公司的流动比率为 5.41，速动比率为 5.41，负债权益比为 0.61。</p>
<h2>内部人员活动</h2>
<p>另外，首席执行官 Laura E. Niklason 于 6 月 11 日星期二以每股 7.08 美元的平均价格出售了 358,630 股股票。此次交易总价值为 2,539,100.40 美元。交易完成后，首席执行官直接持有公司股票 4,830,658 股，价值 34,201,058.64 美元。该交易已在提交给美国证券交易委员会（SEC）的文件中披露，可通过 SEC 网站查看。此外，董事 Brady W. Dougan 于 6 月 12 日星期三以每股 7.30 美元的平均价格出售了 271,518 股公司股票。此次交易总价值为 1,982,081.40 美元。交易完成后，该董事直接持有公司股票 4,559,140 股，价值 33,281,722 美元。该交易已在提交给 SEC 的文件中披露，可通过此超链接查看。此外，首席执行官 Laura E. Niklason 于 6 月 11 日星期二以每股 7.08 美元的平均价格出售了 358,630 股 Humacyte 股票。此次交易总价值为 2,539,100.40 美元。交易完成后，首席执行官在公司中持有 4,830,658 股股票，价值 34,201,058.64 美元。上一季度内部人员共出售了价值 10,508,440 美元的 1,551,415 股公司股票。目前公司股份的 23.10% 由内部人员持有。</p>
<h2>对 Humacyte 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近对其股票持仓进行了调整。nVerses Capital LLC 在第二季度购入了 Humacyte 股票，价值 28,000 美元。Victory Capital Management Inc.在第四季度购入了 Humacyte 股票，价值约 29,000 美元。Kovitz Investment Group Partners LLC 在第四季度购入了 Humacyte 股票，价值约 35,000 美元。中国通用资产管理有限公司在第一季度将其对 Humacyte 的持股比例提高了 65.9%。中国通用资产管理有限公司现在拥有公司股票 19,883 股，价值 62,000 美元，比上一季度增加了 7,897 股。最后，Hartline Investment Corp 在第一季度购入了 Humacyte 股票，价值约 70,000 美元。目前，44.71% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>Humacyte 公司简介（获取免费报告）</h2>
<p>Humacyte, Inc 致力于开发和制造用于治疗多种解剖部位疾病和症状的离体、可植入和生物工程人类组织。该公司利用其专有的科学技术平台工程和制造人类无细胞血管（HAVs），可植入患者体内而不引起异物反应或导致免疫排斥。</p>
<h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>股市板块：它们是什么以及有多少个</li>
<li>内部人员正在购买的 3 只小市值股票</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>分析师预测西部数据的巨大增长——不要错过</li>
<li>现在购买宝洁股票，趁它创下新的历史高点之前</li>
<li>今天市场上看涨投资者必须拥有的 3 只股票</li>
</ul>
<p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 唯一值得购买的 AI 公司（由波特公司提供）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ2"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Humacyte 股票？</h2>
<p>在考虑购买 Humacyte 股票之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了顶级分析师悄悄告诉客户在更广泛市场注意之前购买的五只股票...而 Humacyte 不在名单上。</p>
<p>尽管 Humacyte 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

HUMA

<p>Humacyte (NASDAQ:HUMA) 周二股价下跌了 8.9%，最低交易价为$0.48，收盘价为$0.51。此次下跌的交易量为 1,366,508 股，远低于平均交易量 2,181,580 股。尽管最近出现下跌，但几位分析师仍然维持对该股票的 “买入” 评级，一致目标价为$0.60。该公司继续开发用于医疗用途的生物工程人体组织</p>

<p>Humacyte, Inc. (NASDAQ:HUMA - Get Free Report)'s stock price fell 8.9% during trading on Tuesday . The stock traded as low as $5.48 and last traded at $5.51. 1,366,508 shares changed hands during trading, a decline of 37% from the average session volume of 2,181,580 shares. The stock had previously closed at $6.05.</p>
<div class="lb-trans"><p>Humacyte, Inc.（纳斯达克股票代码：HUMA - 获取免费报告）的股价在周二交易中下跌了 8.9%。股价最低达到 5.48 美元，最后交易价为 5.51 美元。在交易过程中，共有 1,366,508 股股票交易，较平均交易量 2,181,580 股下降了 37%。该股票此前收盘价为 6.05 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research analysts recently issued reports on the company. BTIG Research raised their target price on Humacyte from $8.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, July 15th. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $7.00 price target on shares of Humacyte in a report on Tuesday, July 2nd. Finally, Benchmark reiterated a &#34;buy&#34; rating and set a $15.00 price objective on shares of Humacyte in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.60.</p>
<div class="lb-trans"><p>近期有几位研究分析师发布了关于该公司的报告。BTIG 研究将 Humacyte 的目标股价从 8.00 美元上调至 11.00 美元，并在 7 月 15 日星期一的一份研究报告中给予该股票 “买入” 评级。康泰菲兹杰拉德重申了对 Humacyte 的 “超重” 评级，并在 7 月 2 日星期二的一份报告中设定了 7.00 美元的价格目标。最后，Benchmark 重申了对 Humacyte 的 “买入” 评级，并在 8 月 12 日星期一的一份研究报告中设定了 15.00 美元的价格目标。一位研究分析师对该股票进行了持有评级，而另外四位则给予了该股票买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “中等买入”，目标股价为 8.60 美元。</p>
</div><p><strong>Check Out Our Latest Report on HUMA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 HUMA 的最新报告</strong></p>
</div><h2>Humacyte Stock Down 8.8 %</h2>
<div class="lb-trans"><h2>Humacyte 股价下跌 8.8%</h2>
</div><p>The company has a market cap of $657.34 million, a P/E ratio of -5.57 and a beta of 1.52. The stock's 50-day moving average price is $6.86 and its 200-day moving average price is $5.47. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.</p>
<div class="lb-trans"><p>该公司的市值为 6.5734 亿美元，市盈率为-5.57，β系数为 1.52。该股票的 50 天移动平均价格为 6.86 美元，200 天移动平均价格为 5.47 美元。该公司的流动比率为 5.41，速动比率为 5.41，负债权益比为 0.61。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人员活动</h2>
</div><p>In other news, CEO Laura E. Niklason sold 358,630 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $7.08, for a total value of $2,539,100.40. Following the completion of the sale, the chief executive officer now directly owns 4,830,658 shares of the company's stock, valued at $34,201,058.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Brady W. Dougan sold 271,518 shares of the company's stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the transaction, the director now directly owns 4,559,140 shares of the company's stock, valued at $33,281,722. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 358,630 shares of Humacyte stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $7.08, for a total value of $2,539,100.40. Following the sale, the chief executive officer now owns 4,830,658 shares in the company, valued at $34,201,058.64. The disclosure for this sale can be found here. Insiders sold a total of 1,551,415 shares of company stock worth $10,508,440 over the last quarter. 23.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>另外，首席执行官 Laura E. Niklason 于 6 月 11 日星期二以每股 7.08 美元的平均价格出售了 358,630 股股票。此次交易总价值为 2,539,100.40 美元。交易完成后，首席执行官直接持有公司股票 4,830,658 股，价值 34,201,058.64 美元。该交易已在提交给美国证券交易委员会（SEC）的文件中披露，可通过 SEC 网站查看。此外，董事 Brady W. Dougan 于 6 月 12 日星期三以每股 7.30 美元的平均价格出售了 271,518 股公司股票。此次交易总价值为 1,982,081.40 美元。交易完成后，该董事直接持有公司股票 4,559,140 股，价值 33,281,722 美元。该交易已在提交给 SEC 的文件中披露，可通过此超链接查看。此外，首席执行官 Laura E. Niklason 于 6 月 11 日星期二以每股 7.08 美元的平均价格出售了 358,630 股 Humacyte 股票。此次交易总价值为 2,539,100.40 美元。交易完成后，首席执行官在公司中持有 4,830,658 股股票，价值 34,201,058.64 美元。上一季度内部人员共出售了价值 10,508,440 美元的 1,551,415 股公司股票。目前公司股份的 23.10% 由内部人员持有。</p>
</div><h2>Hedge Funds Weigh In On Humacyte</h2>
<div class="lb-trans"><h2>对 Humacyte 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC bought a new stake in shares of Humacyte in the second quarter valued at $28,000. Victory Capital Management Inc. bought a new stake in shares of Humacyte in the fourth quarter valued at approximately $29,000. Kovitz Investment Group Partners LLC bought a new stake in shares of Humacyte in the fourth quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Humacyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company's stock valued at $62,000 after buying an additional 7,897 shares in the last quarter. Finally, Hartline Investment Corp bought a new position in Humacyte in the 1st quarter worth approximately $70,000. 44.71% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对其股票持仓进行了调整。nVerses Capital LLC 在第二季度购入了 Humacyte 股票，价值 28,000 美元。Victory Capital Management Inc.在第四季度购入了 Humacyte 股票，价值约 29,000 美元。Kovitz Investment Group Partners LLC 在第四季度购入了 Humacyte 股票，价值约 35,000 美元。中国通用资产管理有限公司在第一季度将其对 Humacyte 的持股比例提高了 65.9%。中国通用资产管理有限公司现在拥有公司股票 19,883 股，价值 62,000 美元，比上一季度增加了 7,897 股。最后，Hartline Investment Corp 在第一季度购入了 Humacyte 股票，价值约 70,000 美元。目前，44.71% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Humacyte Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Humacyte 公司简介（获取免费报告）</h2>
</div><p>Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.</p>
<div class="lb-trans"><p>Humacyte, Inc 致力于开发和制造用于治疗多种解剖部位疾病和症状的离体、可植入和生物工程人类组织。该公司利用其专有的科学技术平台工程和制造人类无细胞血管（HAVs），可植入患者体内而不引起异物反应或导致免疫排斥。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Humacyte</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Small Cap Stocks That Insiders Are Buying</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>3 Must-Own Stocks for Bullish Investors in Today's Market</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>股市板块：它们是什么以及有多少个</li>
<li>内部人员正在购买的 3 只小市值股票</li>
<li>什么是债券市场假日？如何投资和交易</li>
<li>分析师预测西部数据的巨大增长——不要错过</li>
<li>现在购买宝洁股票，趁它创下新的历史高点之前</li>
<li>今天市场上看涨投资者必须拥有的 3 只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ The only AI company to buy (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 唯一值得购买的 AI 公司（由波特公司提供）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9246&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Humacyte right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Humacyte 股票？</h2>
</div><p>Before you consider Humacyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Humacyte 股票之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了顶级分析师悄悄告诉客户在更广泛市场注意之前购买的五只股票...而 Humacyte 不在名单上。</p>
</div><p>While Humacyte currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Humacyte 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Humacyte（纳斯达克代码：HUMA）股价下跌 8.9%